Skip to content

Impact of Spin on the Interpretation of Results of Randomized Trials in the Field of Cancer

Impact of Spin on the Interpretation of Results of Randomized Trials in the Field of Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01848704
Acronym
SPIIN
Enrollment
300
Registered
2013-05-07
Start date
2013-05-31
Completion date
2013-06-30
Last updated
2024-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the Study Focus on no Specific Condition

Keywords

spin, interpretation, bias

Brief summary

Randomized controlled trials (RCT) are the gold standard for therapeutic evaluation. Rapid dissemination of trial results and their translation into clinical practice is particularly important. Abstracts published or presented in conferences are a large, rapid and free method to disseminate these results. However, this mode of dissemination may have serious consequences for patients if abstracts are not an accurate and unbiased reflection of the trial results. Investigators have great freedom when writing their abstracts and articles: they can choose the data and decide how to present it. Consequently, they have many opportunities to shape readers' impressions of their results, that is, to add spin (ie, spin is a specific way of reporting to convince readers that the beneficial effect of the experimental treatment is higher than shown by the results). Objective: To assess the impact of spin on the interpretation of results in abstracts of randomized controlled trials with non-statistically significant results in the field of cancer.

Detailed description

The investigators planned a RCT in which the unit of randomization is the abstract. The planning, implementation, analysis and writing of this study followed the CONSORT Statement12. Design The investigators performed a RCT comparing the interpretation of results in abstracts a) with and b) without spin. 1. Identification of abstracts of randomized trials with spin. The investigators selected a sample of negative published RCTs (i.e. non statistically significant results) with a spin in abstract conclusion identified in previous works. Inclusion criteria were 1) RCTs with non-statistically significant primary outcome, 2) spin in the abstract conclusion. 2. Abstracts' modification Selected abstracts were systematically rewritten to contain no spin. All abstracts were presented in the same format without the names of authors, references, or the name of the journal in which it was published, and the names of treatments were masked by using generic terms. 3. Assessment Abstracts were assessed by corresponding authors of randomized trials, experts of specific grants and investigator of trials registered in http://clinicaltrials.gov. Experts were invited to participate in our study. They were not informed of the objectives of our study. Each clinician was randomized to evaluate 1 abstract with or 1 abstract without spin. 4. The primary endpoint was the interpretation of abstract results by participants. All readers participating in the study evaluated the abstract of randomized trial and answered the following question: Based on this abstract, do you think treatment A would be beneficial to patients? Randomization characteristics The randomization list was established in blocks of 30. So, each participant could evaluate 1 abstract with spin or 1 abstract with no spin. The list and the block size were not disclosed to investigators. Allocation concealment was obtained by use of a computerized randomization system. If a participant logged on the system but did not evaluate any abstract, the assessments were excluded and the abstracts were automatically allocated to the next participant. Eligibility criteria Evaluators participating in this study were as follows: 1. The corresponding authors of published RCTs in the field of cancer. The investigators systematically searched Medline via PubMed to identify all publications of RCTs in 2012 and if needed 2011, 2010. The investigators collected all e-mails of corresponding authors of these items. 2. Experts of a French national grant in the field of cancer All potential participants were invited by e-mail to participate in a study on the interpretation of results of abstracts of clinical trials. If they agreed to participate, they used an Internet link that gave them access to abstracts to assess. 3. Investigators of trials registered in http://clinicaltrials.gov. Intervention and comparators Selection of abstracts with spin We selected from previous work and personnel collection13-16, 30 abstracts of 2 parallel arms negative RCTs (ie, non-statistically significant primary outcome) evaluating treatment in the field of cancer and having spin in the abstract conclusion according to a classification developed previously13. We excluded abstract with very unusual type of spin such as a focus on another study objective, with spin related only to safety, or study comparing the same treatment but with different dosage or different mode of administration or different duration of treatment. We also excluded abstract of RCTs with small sample size (\<100). Abstract were numbered from 1 to 30 and were classified in two categories: 10 abstracts (numbers 11/12/14/16/20/22/24/27/28/30) with high level of spin (i.e., no acknowledgment of the non statistically significant primary outcome in the conclusion) and 20 with low level of spin. Development of abstracts without spin The abstracts with spin were systematically rewritten without spin. One researcher rewrote each abstract according to specific guidelines described in the box. All abstracts had the same number of words +/-25. All abstracts without spin were evaluated independently by another researcher any disagreement were discussed and the abstract was modified according to the consensus reached. Thus, for each study, the investigators had 2 versions of the abstract: 1 with spin and 1 without spin. Abstracts with and without spin were presented in the format of the original abstract with the same typography. The names of authors, references, journal name, registration number, trial name or acronym, and article title were deleted, and the treatment names and description were systematically masked with generic terms (e.g., treatment A and comparator B). If needed some information that could help identifying the treatment were deleted. Outcomes Primary outcome The primary endpoint was participants' interpretation of the abstracts. All study participants evaluated each abstract. They answered the following question on a numerical scale graded from 0 (not at all likely) to 10 (very likely) • Based on this abstract, do you think treatment A would be beneficial to patients? (answer: numerical scale from 0-10) Secondary outcomes The secondary endpoints were the assessment of the study quality, the study importance, the interest in reading the full text and the probability of being published. For each abstract, the participants answered the following: * Rate the overall rigor of the study methodology? (scale 0-10) * Rate the importance of the study (scale 0-10) * Are you interested in reading the full article for the study described in this abstract? (scale 0-10) * Do you think it would be interesting to run another trial evaluating this treatment? (scale 0-10) Blinding The primary endpoint is the interpretation of the abstract by participants. This outcome is very subjective. A recent study has shown that lack of blinding is responsible for an overestimation of treatment effect in randomized trials with subjective primary endpoints17. To minimize bias, the investigators proposed to have participants blinded to the study hypothesis. All participants were informed that they were participating in a survey on the interpretation of abstracts of clinical trials. They were not informed of the objectives and assumptions of the study before the end of the study when reporting the results. Other data collected The investigators also collected the changes to abstracts in terms of words deleted and words added to each abstract. Sample size Each participant will read 1 abstract with or 1 abstract without spin. A sample of 266 assessments of abstracts is needed to show an effect size of 0.4 with primary outcome assuming a mean difference of 1 point and a common standard deviation based on a pilot study of 2.5 with a power of 90% and an alpha risk equal to 5%. Thirty abstracts with spin and 30 abstracts without spin are available. Theoretically, each abstract must be read the same number of times according to randomization group. Considering all these elements, it will be necessary to include 300 participants (150 in each arm). Each abstract will be read 5 times in each group (abstract with low level of spin will be read 200 times (100 in each group) and abstract with high level of spin will be read 100 times (50 in each group)). Statistical analysis Statistical analysis will be undertaken independently and blindly with use of Statistical Analysis Software (SAS) v9.3 by a statistician of the Centre for Clinical Epidemiology. A statistical analytic plan will be developed and validated before searching the database. The statistical analysis plan will be revised during the study to take into account any amendments to the protocol or any other change having an impact on the statistical analysis originally planned. All versions will be kept on file for review. A T test will be used for analysis of primary and secondary outcomes. This statistical plan can be modified according to available data. For instance, if the number of readings for a particular vignette is unbalanced in groups, a multi-level model (a mixed model for clustered data) will be used to compare adjusted means for the primary outcome measures between the 2 arms. This means that statistical analysis will be adjusted for unbalanced repartition of abstracts in each group. The same model will be applied to secondary outcomes and to the subgroup abstracts with high level of spin. A secondary analysis will compare the Intraclass Correlation (ICC) between readers of abstracts with spin and abstracts without spin by computing the 95% confidence interval of the difference between ICCs (by a bootstrap method).

Interventions

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

The evaluators participating in this study were as follows: The corresponding authors of published RCTs in the field of cancer Experts of a French national grant in the field of cancer -investigator of trials registered in clinicaltrials.gov

Design outcomes

Primary

MeasureTime frameDescription
Interpretation of the Beneficial Effect of the Experimental Treatment1 monthThe primary endpoint was the interpretation of abstract results by the participants. All readers participating in the study evaluated the abstracts of randomized trials and answered the following questions: based on this abstract, do you think treatment A would be beneficial to patients? (answer: numerical scale from 0 not at all likely tp 10 very likely)

Secondary

MeasureTime frameDescription
Overall Rigor of the Study Methodology1 monthFor each abstract, the participants answered the following: * Rate the overall rigor of the study methodology(scale 0-10) * Rate the importance of the study (scale 0-10) * Are you interested in reading the full text article for the study described in this abstract? (scale 0-10) * Do you think it would be interesting to run another trial evaluating this treatment? (scale 0-10) (Numerical scale from 0 not at all likely tp 10 very likely)
Importance of the Study1 monthFor each abstract, the participants answered the following: •Rate the importance of the study (scale from 0 not at all likely tp 10 very likely)
Interest in Reading Full Text1 monthFor each abstract, the participants answered the following: •Are you interested in reading the full text article for the study described in this abstract? (scale from 0 not at all likely tp 10 very likely)
Need for More Evidence (Run a New Trial)1 monthFor each abstract, the participants answered the following: •do you think it would be interesting to run another trial evaluating this treatment? (scale 0-10) (answer: numerical scale from 0 not at all likely tp 10 very likely

Countries

France

Participant flow

Participants by arm

ArmCount
Abstract With Spin
30 abstracts of 2 parallel arms negative RCTs (ie, non-statistically significant primary outcome) evaluating treatment in the field of cancer and having spin in the abstract conclusion according to a classification developed previously interpretation of the abstract
150
Abstract Without Spin
The abstracts with spin were systematically rewritten without spin interpretation of the abstract
150
Total300

Baseline characteristics

CharacteristicAbstract With SpinAbstract Without SpinTotal
Age, Continuous47.0 years
STANDARD_DEVIATION 9.7
48.3 years
STANDARD_DEVIATION 9.9
47.7 years
STANDARD_DEVIATION 9.8
Current practice
Primary care center
25 Participants35 Participants60 Participants
Current practice
Secondary care center
15 Participants9 Participants24 Participants
Current practice
Tertiary care center
110 Participants106 Participants216 Participants
Duration of practice, years
>15
81 Participants84 Participants165 Participants
Duration of practice, years
<5
6 Participants8 Participants14 Participants
Duration of practice, years
5-15
63 Participants58 Participants121 Participants
Graduate degree
MD
73 Participants82 Participants155 Participants
Graduate degree
MD/PhD
71 Participants62 Participants133 Participants
Graduate degree
Other
6 Participants6 Participants12 Participants
Location
Asia
6 Participants10 Participants16 Participants
Location
Canada
12 Participants8 Participants20 Participants
Location
Europe
84 Participants85 Participants169 Participants
Location
Oceania
8 Participants4 Participants12 Participants
Location
South America
6 Participants0 Participants6 Participants
Location
United States
34 Participants43 Participants77 Participants
No. of abstracts of randomized trials read in the last month
10 to 15
31 Participants31 Participants62 Participants
No. of abstracts of randomized trials read in the last month
>15
46 Participants47 Participants93 Participants
No. of abstracts of randomized trials read in the last month
<5
22 Participants24 Participants46 Participants
No. of abstracts of randomized trials read in the last month
5 to 10
51 Participants48 Participants99 Participants
No. of articles peer reviewed in the last year
> 10
55 Participants47 Participants102 Participants
No. of articles peer reviewed in the last year
<5
47 Participants53 Participants100 Participants
No. of articles peer reviewed in the last year
5 to 10
48 Participants50 Participants98 Participants
No. of grant proposals peer reviewed in the last year
> 10
20 Participants17 Participants37 Participants
No. of grant proposals peer reviewed in the last year
<5
110 Participants112 Participants222 Participants
No. of grant proposals peer reviewed in the last year
5 to 10
20 Participants21 Participants41 Participants
No. of randomized trials involved in
> 10 trials
76 Participants71 Participants147 Participants
No. of randomized trials involved in
< 3 trials
35 Participants36 Participants71 Participants
No. of randomized trials involved in
4 to 10 trials
39 Participants43 Participants82 Participants
No. of randomized trials published as a corresponding
> 10
17 Participants22 Participants39 Participants
No. of randomized trials published as a corresponding
< 3
96 Participants89 Participants185 Participants
No. of randomized trials published as a corresponding
4 to 10
37 Participants39 Participants76 Participants
Sex: Female, Male
Female
26 Participants39 Participants65 Participants
Sex: Female, Male
Male
124 Participants111 Participants235 Participants
Some training in epidemiology73 Participants69 Participants142 Participants
Some training in the methods of randomized trials114 Participants121 Participants235 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 1500 / 150
other
Total, other adverse events
0 / 1500 / 150
serious
Total, serious adverse events
0 / 1500 / 150

Outcome results

Primary

Interpretation of the Beneficial Effect of the Experimental Treatment

The primary endpoint was the interpretation of abstract results by the participants. All readers participating in the study evaluated the abstracts of randomized trials and answered the following questions: based on this abstract, do you think treatment A would be beneficial to patients? (answer: numerical scale from 0 not at all likely tp 10 very likely)

Time frame: 1 month

ArmMeasureValue (MEAN)Dispersion
Abstract With SpinInterpretation of the Beneficial Effect of the Experimental Treatment3.6 score on a scaleStandard Deviation 2.5
Abstract Without SpinInterpretation of the Beneficial Effect of the Experimental Treatment2.9 score on a scaleStandard Deviation 2.6
p-value: 0.0395% CI: [0.07, 1.35]Mixed Models Analysis
Secondary

Importance of the Study

For each abstract, the participants answered the following: •Rate the importance of the study (scale from 0 not at all likely tp 10 very likely)

Time frame: 1 month

ArmMeasureValue (MEAN)Dispersion
Abstract With SpinImportance of the Study4.6 score on a scaleStandard Deviation 2.4
Abstract Without SpinImportance of the Study4.9 score on a scaleStandard Deviation 2.4
p-value: 0.1895% CI: [-0.95, 0.19]Mixed Models Analysis
Secondary

Interest in Reading Full Text

For each abstract, the participants answered the following: •Are you interested in reading the full text article for the study described in this abstract? (scale from 0 not at all likely tp 10 very likely)

Time frame: 1 month

ArmMeasureValue (MEAN)Dispersion
Abstract With SpinInterest in Reading Full Text5.1 score on a scaleStandard Deviation 3.2
Abstract Without SpinInterest in Reading Full Text4.3 score on a scaleStandard Deviation 3
p-value: 0.02995% CI: [0.08, 1.47]Mixed Models Analysis
Secondary

Need for More Evidence (Run a New Trial)

For each abstract, the participants answered the following: •do you think it would be interesting to run another trial evaluating this treatment? (scale 0-10) (answer: numerical scale from 0 not at all likely tp 10 very likely

Time frame: 1 month

ArmMeasureValue (MEAN)Dispersion
Abstract With SpinNeed for More Evidence (Run a New Trial)4.8 score on a scaleStandard Deviation 2.9
Abstract Without SpinNeed for More Evidence (Run a New Trial)4.2 score on a scaleStandard Deviation 2.9
p-value: 0.06195% CI: [-0.03, 1.31]Mixed Models Analysis
Secondary

Overall Rigor of the Study Methodology

For each abstract, the participants answered the following: * Rate the overall rigor of the study methodology(scale 0-10) * Rate the importance of the study (scale 0-10) * Are you interested in reading the full text article for the study described in this abstract? (scale 0-10) * Do you think it would be interesting to run another trial evaluating this treatment? (scale 0-10) (Numerical scale from 0 not at all likely tp 10 very likely)

Time frame: 1 month

ArmMeasureValue (MEAN)Dispersion
Abstract With SpinOverall Rigor of the Study Methodology4.5 score on a scaleStandard Deviation 2.4
Abstract Without SpinOverall Rigor of the Study Methodology5.1 score on a scaleStandard Deviation 2.5
p-value: 0.0395% CI: [-1.13, -0.05]Mixed Models Analysis

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026